No CRS summary available for this bill.
This section revises the Medicare Drug Price Negotiation Program—under which the Department of Health and Human Services selects high-cost, single-source Part D drugs for negotiation of maximum fair prices—effective for initial price applicability years beginning with 2028, by (1) increasing the maximum number of negotiation-eligible drugs that may be selected for 2028 and subsequent years to 50 (from 15) and striking the separate provision for subsequent years; (2) shortening, in the definition of qualifying single source drug, the exclusion period for drugs approved under specified FDA pathways from 7 years to 3 years and for biological products licensed under specified FDA pathways from 11 years to 3 years; and (3) revising the upper limits on maximum fair prices to 76 percent (from 75 percent) for drugs less than 9 years after introduction, 55 percent (from 65 percent) for drugs 9–12 years after introduction, and 30 percent (from 40 percent) for drugs more than 12 years after introduction.